Figure 4. Dosage of serum bone metabolism biomarkers (a) RANKL, (b) osteoprotegerin, (c) DKK-1, (d) sFRP-1, (e) osteopontin, (f) bone-specific alkaline phosphatase and (g) sclerostin in seven patients with PDB pre-treatment with zoledronic acid and after three months. Each line represents the results of an individual patient.

RANKL - receptor activator of nuclear factor kappa-Β ligand, DKK-1 - Dickkopf-related protein-1, sFRP-1 - soluble frizzled-related protein 1, PDB - Paget’s disease of bone